GlassScriptPhysician profile
Nizar Ramzan
NPI 1992733992
$13,826.65
in general payments reported to CMS, 2019-2025
42 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $1,283 · 2021: $2,239 · 2022: $2,650 · 2023: $2,809 · 2024: $3,208 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,109 · Education: $37.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,108.85 |
| Education | $37.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,778.85 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,823.96 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,278.38 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $1,127.76 | 2019-2024 | |
| Gilead Sciences, INC. | $930.08 | 2019-2024 | |
| Celgene Corporation | $675.89 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $570.33 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $499.08 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $494.05 | 2019-2024 | Rebyota, Cimzia, Clenpiq |
| Janssen Biotech, INC. | $473.93 | 2019-2025 | Stelara, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $323.43 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $300.98 | 2019-2024 | Sucraid |
| Ardelyx, INC. | $269.44 | 2022-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $261.45 | 2019-2024 | Ocaliva |
| Daiichi Sankyo INC. | $216.46 | 2020-2023 | Injectafer |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $163.70 | 2022-2024 | |
| Ucb, INC. | $151.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.85 | 2020-2024 | Dificid |
| Alfasigma USA, INC. | $122.05 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $113.23 | 2023-2024 | Voquezna |
| Lilly USA, LLC | $110.43 | 2024 | Omvoh, Zepbound |
| Mylan Institutional INC. | $106.31 | 2023 | Hulio |
| Aimmune Therapeutics, INC. | $96.38 | 2024 | |
| Amgen INC. | $95.46 | 2021-2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $93.89 | 2020-2021 | |
| Celltrion USA INC. | $87.49 | 2023-2024 | Vegzelma, Yuflyma |
| Braintree Laboratories, INC. | $67.89 | 2021-2024 | Suflave |
| Ipsen Biopharmaceuticals, INC | $63.40 | 2024 | Iqirvo, Bylvay |
| Lucid Diagnostics INC. | $44.25 | 2024 | |
| Biocon Biologics INC | $44.24 | 2024 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.49 | 2023 | Cyltezo |
| Novo Nordisk INC | $41.31 | 2023-2024 | Wegovy |
| Evoke Pharma, INC. | $40.10 | 2024 | |
| Allergan, INC. | $31.55 | 2019-2020 | |
| Medtronic, INC. | $30.52 | 2021-2024 | Interstim |
| Alnylam Pharmaceuticals INC. | $29.01 | 2024 | Givlaari |
| Pharmacosmos Therapeutics INC. | $22.69 | 2020 | |
| Csl Behring | $20.18 | 2023 | Kcentra |
| Capsovision, INC. | $19.10 | 2023 | Capsocam Plus |
| Amag Pharmaceuticals, INC. | $14.56 | 2019 | |
| Axonics, INC. | $12.93 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nizar Ramzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.